{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:34:38Z","timestamp":1786808078236,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BEDWEL23G0-COLLAB"],"award-info":[{"award-number":["BEDWEL23G0-COLLAB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Lab","doi-asserted-by":"publisher","award":["BEDWEL19G0"],"award-info":[{"award-number":["BEDWEL19G0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Lab","doi-asserted-by":"publisher","award":["DAVIS24R0"],"award-info":[{"award-number":["DAVIS24R0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["2P30DK072482-14"],"award-info":[{"award-number":["2P30DK072482-14"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:37:40Z","timestamp":1759009060000},"page":"106-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutations"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-1686","authenticated-orcid":false,"given":"Kari","family":"Thrasher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-1875","authenticated-orcid":false,"given":"Jianguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianwu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2131-4383","authenticated-orcid":false,"given":"Jenna","family":"Ekstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra A.","family":"Hargett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Renfrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-5858","authenticated-orcid":false,"given":"Kim M.","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-818X","authenticated-orcid":false,"given":"David M.","family":"Bedwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2025.09.006_bib0001","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jcf.2025.09.006_bib0002","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with Cystic Fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.jcf.2025.09.006_bib0003","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.09.006_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"384","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.09.006_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcf.2025.09.006_bib0006","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2025.09.006_bib0007","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jcf.2025.09.006_bib0008","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.09.006_bib0009","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"issue":"16","key":"10.1016\/j.jcf.2025.09.006_bib0010","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1002\/j.1460-2075.1995.tb00078.x","article-title":"Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3","volume":"14","author":"Zhouravleva","year":"1995","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.jcf.2025.09.006_bib0011","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1101\/gr.119974.110","article-title":"Evidence of abundant stop codon readthrough in Drosophila and other metazoa","volume":"21","author":"Jungreis","year":"2011","journal-title":"Genome Res"},{"issue":"14","key":"10.1016\/j.jcf.2025.09.006_bib0012","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1093\/nar\/gku608","article-title":"Evidence of efficient stop codon readthrough in four mammalian genes","volume":"42","author":"Loughran","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.jcf.2025.09.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002608","article-title":"Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin","volume":"8","author":"Floquet","year":"2012","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.006_bib0014","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat Commun"},{"issue":"7140","key":"10.1016\/j.jcf.2025.09.006_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"issue":"2\u20133","key":"10.1016\/j.jcf.2025.09.006_bib0016","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF02464911","article-title":"Aminoglycoside suppression at UAG, UAA and UGA codons in Escherichia coli and human tissue culture cells","volume":"217","author":"Martin","year":"1989","journal-title":"Mol Gen Genet"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.006_bib0017","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jcf.2025.09.006_bib0018","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jcf.2025.09.006_bib0019","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr-\/- mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J Mol Med"},{"issue":"44","key":"10.1016\/j.jcf.2025.09.006_bib0020","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.jcf.2025.09.006_bib0021","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/hmg\/ddx196","article-title":"Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences","volume":"26","author":"Xue","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.006_bib0022","doi-asserted-by":"crossref","first-page":"L756","DOI":"10.1152\/ajplung.00038.2023","article-title":"The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators","volume":"324","author":"Chen","year":"2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.006_bib0023","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1006\/jmbi.2000.4419","article-title":"Structure of a eukaryotic decoding region A-site RNA","volume":"306","author":"Lynch","year":"2001","journal-title":"J Mol Biol"},{"issue":"4 Pt 1","key":"10.1016\/j.jcf.2025.09.006_bib0024","first-page":"L405","article-title":"Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium","volume":"266","author":"Sheppard","year":"1994","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.006_bib0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.jcf.2025.09.006_bib0026","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jcf.2022.10.010","article-title":"The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough","volume":"22","author":"Pranke","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.006_bib0027","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/biom11071006","article-title":"Stop codon context-specific induction of translational readthrough","volume":"11","author":"Schilff","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcf.2025.09.006_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"ELife"},{"key":"10.1016\/j.jcf.2025.09.006_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-5-5","article-title":"In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study","volume":"5","author":"Sermet-Gaudelus","year":"2007","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.006_bib0030","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1038\/s41467-024-46703-z","article-title":"Extended stop codon context predicts nonsense codon readthrough efficiency in human cells","volume":"15","author":"Mangkalaphiban","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jcf.2025.09.006_bib0031","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/s41588-024-01878-5","article-title":"Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules","volume":"56","author":"Toledano","year":"2024","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.006_bib0032","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jcf.2024.07.017","article-title":"TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR","volume":"23","author":"Karri","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.006_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/biom13060988","article-title":"Pharmaceuticals promoting premature termination codon readthrough: progress in development","volume":"13","author":"Li","year":"2023","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.jcf.2025.09.006_bib0034","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/biomedicines11030659","article-title":"Recoding of nonsense mutation as a pharmacological strategy","volume":"11","author":"Temaj","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.006_bib0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","article-title":"Pharmacologic therapy for stop mutations: how much CFTR activity is enough?","volume":"10","author":"Kerem","year":"2004","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.006_bib0036","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.09.006_bib0037","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jcf.2025.09.006_bib0038","article-title":"Eloxx Pharmaceuticals announces final data assessment from phase 2 combination clinical trial of ELX-02 in class 1 cystic fibrosis (CF) patients","year":"2023","journal-title":"Globe Newswire"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.006_bib0039","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.gt.3302211","article-title":"Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment","volume":"11","author":"Bidou","year":"2004","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.006_bib0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system","volume":"80","author":"Keeling","year":"2002","journal-title":"J Mol Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.006_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1355838200991660","article-title":"mRNA surveillance in mammalian cells: the relationship between introns and translation termination","volume":"6","author":"Sun","year":"2000","journal-title":"RNA"},{"issue":"9","key":"10.1016\/j.jcf.2025.09.006_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12091448","article-title":"Downstream alternate start site allows N-terminal nonsense variants to escape NMD and results in functional recovery by readthrough and modulator combination","volume":"12","author":"Bowling","year":"2022","journal-title":"J Pers Med"},{"issue":"14","key":"10.1016\/j.jcf.2025.09.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"issue":"7351","key":"10.1016\/j.jcf.2025.09.006_bib0044","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10165","article-title":"Converting nonsense codons into sense codons by targeted pseudouridylation","volume":"474","author":"Karijolich","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2025.09.006_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature12302","article-title":"Unusual base pairing during the decoding of a stop codon by the ribosome","volume":"500","author":"Fernandez","year":"2013","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.jcf.2025.09.006_bib0046","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1093\/nar\/gku663","article-title":"New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae","volume":"42","author":"Blanchet","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.jcf.2025.09.006_bib0047","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1093\/nar\/gkr224","article-title":"Stimulation of stop codon readthrough: frequent presence of an extended 3\u2032 RNA structural element","volume":"39","author":"Firth","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.jcf.2025.09.006_bib0048","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/cells10102793","article-title":"Therapeutic approaches for patients with cystic fibrosis not eligible for current CFTR modulators","volume":"10","author":"Fajac","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01177-18","article-title":"Defining HIV-1 envelope N-glycan microdomains through site-specific heterogeneity profiles","volume":"93","author":"Hargett","year":"2018","journal-title":"J Virol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325016121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325016121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:44:31Z","timestamp":1773157471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325016121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325016121"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.09.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}